Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT00769223

Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer

Pre-Operative Gleason Score and PSA and Clinical Stage in Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer

Status
Active Not Recruiting
Phase
Study type
Observational
Enrollment
3,561 (actual)
Sponsor
University of California, San Francisco · Academic / Other
Sex
Male
Age
18 Years – 120 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Gathering information about the Gleason score, prostate-specific antigen (PSA) level, and cancer stage from patients who have undergone radiation therapy for prostate cancer may help doctors predict how patients respond to treatment and help plan the best treatment. PURPOSE: This clinical trial is studying the Gleason score, PSA level, and cancer stage in predicting outcome in patients who have undergone radiation therapy for localized prostate cancer.

Detailed description

OBJECTIVES: * Evaluate the value of the pre-operative Gleason score, prostate-specific antigen level, and clinical stage in predicting the risk of failure and death in patients who have undergone radiotherapy for localized prostate cancer. OUTLINE: This is a multicenter study. Patient medical records are reviewed to collect data about pre-treatment prostate biopsy, assigned Gleason score, prostate-specific antigen level, and radionucleotide bone scan. Patients complete a Bowel Toxicity questionnaire to assess quality of life related to acute and long-term bowel toxicity after radiotherapy.

Conditions

Interventions

TypeNameDescription
OTHERmedical chart review
OTHERquestionnaire administration
PROCEDUREquality-of-life assessment
RADIATIONbrachytherapy
RADIATIONradiation therapy

Timeline

Start date
1993-02-25
Primary completion
2026-01-31
Completion
2026-01-31
First posted
2008-10-09
Last updated
2025-03-20

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00769223. Inclusion in this directory is not an endorsement.